|
|
||||||||
Papers In Press, published online ahead of print March 1, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pediatrics Dept., Washington University School of Medicine, St. Louis, MO 63110
Corresponding Author: LI_YO{at}kids.wustl.edu
Familial hypercholesterolemia is a genetic disorder which results from various gene mutations primarily within the low-density lipoprotein receptor (LDLR). Approximately 50% of the LDLR mutations are defined as class 2 mutations with the mutant proteins partially or entirely retained in the endoplasmic reticulum (ER). To determine the degradation pathway of the LDLR class 2 mutants, we examined effects of inhibition of several potential pathways on the levels of the wild-type LDLR and its four representative class 2 mutants (S156L, C176Y, E207K, and C646Y) stably expressed in Chinese hamster ovary cells. We found that proteasome inhibitors MG132 and lactacystin blocked the degradation of the LDLR mutants, but not that of the wild-type LDLR. Treatment of CHO cells with these proteasome inhibitors led to a significant accumulation of the mutants at steady-state. Furthermore, cell surface levels of the LDLR mutants were significantly increased upon inhibition of the proteasome degradation pathway. In contrast to the proteasome inhibitors, inhibitors of trypsin-like proteases, chymotrypsin-like proteases, and lysosomal pathway inhibitors did not affect the levels of the LDLR mutants. Taken together, these data demonstrate that the proteasome is the principal degradation pathway for LDLR class 2 mutants.
Revised on February 6, 2004
Accepted on February 26, 2004
Degradation of the low-density lipoprotein receptor class 2 mutants is mediated by a proteasome-dependent pathway
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
E. R. Eden, X.-M. Sun, D. D. Patel, and A. K. Soutar Adaptor protein Disabled-2 modulates low density lipoprotein receptor synthesis in fibroblasts from patients with autosomal recessive hypercholesterolaemia Hum. Mol. Genet., November 15, 2007; 16(22): 2751 - 2759. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sorensen, T. Ranheim, K. S. Bakken, T. P. Leren, and M. A. Kulseth Retention of Mutant Low Density Lipoprotein Receptor in Endoplasmic Reticulum (ER) Leads to ER Stress J. Biol. Chem., January 6, 2006; 281(1): 468 - 476. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Castro-Fernandez, G. Maya-Nunez, and P. M. Conn Beyond the Signal Sequence: Protein Routing in Health and Disease Endocr. Rev., June 1, 2005; 26(4): 479 - 503. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. N. Maxwell, E. A. Fisher, and J. L. Breslow Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment PNAS, February 8, 2005; 102(6): 2069 - 2074. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |